Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Budesonide Nebuliser Suspension (08P1707F0)
NCT06595121Phase 1Completed
- Sponsor
- Unither Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of budesonide in asthma (4 arms), sponsored by Unither Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration (Cmax) of budesonide at 24.00 hours and Area Under the Curve from time 0 to last measurable concentration (AUC 0-t) of budesonide up to 24 hours. Started Aug 2024; status: completed.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06595121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06595121.